Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer - Contacts and Locations

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

This study is currently recruiting participants.

Study NCT00660101. Last updated on April 16, 2008. Information provided by AVAX Technologies

Please refer to this study by its ClinicalTrials.gov identifier: NCT00660101

Locations


United States, Illinois
	Cancer Treatment Centers of America (CTCA-Midwestern)	Recruiting
	Zion, Illinois, United States, 60099
	Contact: Joy Jardinico, RN 847-731-4143 joy-jardinico@ctca-hope.com
	Principal Investigator: Sybilann Williams, MD

Sponsors and Collaborators

AVAX Technologies

Investigators


Study Director:	David Berd, MD	AVAX Technologies